Quetiapine extended‐release vs olanzapine for Japanese patients with bipolar depression: A Bayesian analysis
Abstract Objective It is unknown whether there are differences in efficacy and safety between quetiapine extended‐release, 300 mg/d (QUEXR300), and olanzapine, 5‐20 mg/d (OLA), for Japanese patients with bipolar depression. Methods We conducted a Bayesian analysis of data from phase 3 studies in Jap...
Saved in:
Main Authors: | Taro Kishi (Author), Toshikazu Ikuta (Author), Yuki Matsuda (Author), Nakao Iwata (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2019-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Lurasidone, olanzapine, and quetiapine extended‐release for bipolar depression: A systematic review and network meta‐analysis of phase 3 trials in Japan
by: Taro Kishi, et al.
Published: (2020) -
Post‐marketing surveillance of quetiapine fumarate extended‐release tablets in patients with bipolar depression
by: Taro Kishi, et al.
Published: (2024) -
A diagnostic test to examine early improvement as a predictor of later response to lurasidone in bipolar depression
by: Taro Kishi, et al.
Published: (2023) -
Electrochemical Studies for the Determination of Quetiapine Fumarate and Olanzapine Antipsychotic Drugs
by: Manal A. El-Shal
Published: (2013) -
Bioequivalence study of tablet forms of risperidone, olanzapine and quetiapine in healthy volunteers
by: V. V. Pisarev, et al.
Published: (2013)